Stocks · News reference

8-K filing — Cytosorbents Corp (CTSO)

Aug 7, 2026, 8:06 PMSEC EDGAR

Filed: 2026-08-07 AccNo: 0001104659-26-092691 Size: 10 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 3, 2026, 11:09 AMBenzinga Newsdesk
Cytosorbents Announces 1-for-20 Reverse Stock Split, Effective September 8
Reverse Stock Split Previously Approved by Shareholders; Intended to Support Compliance with Nasdaq's $1.00 Minimum Bid Price RequirementExpected to Become Effective and Trade on Split-Adjusted Basis at the Market
CTSO
BenzingaSep 2, 2026, 11:30 AMBenzinga Newsdesk
CytoSorbents Says Real-World Matched Analysis Of 587 Urgent CABG Patients On Ticagrelor Showed 37% Relative Reduction In Severe Bleeding With CytoSorb; Plans New DrugSorb-ATR De Novo Submission In Early 2027
CTSO
BenzingaAug 11, 2026, 9:06 PMBenzinga Insights
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 44.4% to $1.56 during Tuesday's after-market session. The company's market cap stands at $4.5 million. As per the news, the Q2 earnings report
ABSI APLM ARAY CCM CRDF